Research programme: NuBiyota/Takeda

Drug Profile

Research programme: NuBiyota/Takeda

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuBiyota
  • Developer NuBiyota; Takeda
  • Class Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Gastrointestinal disorders

Most Recent Events

  • 10 Apr 2017 Takeda and NuBiyota enter into a collaboration for the development of microbiome therapeutics for Gastrointestinal disorders
  • 10 Apr 2017 Early research in Gastrointestinal disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top